Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 1
2010 1
2011 2
2014 1
2015 2
2016 2
2017 3
2019 1
2020 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.
Poulsen TT, Grandal MM, Skartved NJØ, Hald R, Alifrangis L, Koefoed K, Lindsted T, Fröhlich C, Pollmann SE, Eriksen KW, Dahlman A, Jacobsen HJ, Bouquin T, Pedersen MW, Horak ID, Lantto J, Kragh M. Poulsen TT, et al. Among authors: alifrangis l. Clin Cancer Res. 2017 Oct 1;23(19):5923-5935. doi: 10.1158/1078-0432.CCR-17-0782. Epub 2017 Jul 5. Clin Cancer Res. 2017. PMID: 28679766
Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors.
Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR. Alifrangis L, et al. J Pharmacokinet Pharmacodyn. 2020 Feb;47(1):5-18. doi: 10.1007/s10928-019-09663-2. Epub 2019 Nov 2. J Pharmacokinet Pharmacodyn. 2020. PMID: 31679083
Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection.
Khalil IF, Abildrup U, Alifrangis LH, Maiga D, Alifrangis M, Hoegberg L, Vestergaard LS, Persson OP, Nyagonde N, Lemnge MM, Theander TG, Bygbjerg IC. Khalil IF, et al. Among authors: alifrangis lh. J Pharm Biomed Anal. 2011 Jan 5;54(1):168-72. doi: 10.1016/j.jpba.2010.08.009. Epub 2010 Aug 17. J Pharm Biomed Anal. 2011. PMID: 20832961
12 results